JPWO2021229212A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021229212A5 JPWO2021229212A5 JP2022568380A JP2022568380A JPWO2021229212A5 JP WO2021229212 A5 JPWO2021229212 A5 JP WO2021229212A5 JP 2022568380 A JP2022568380 A JP 2022568380A JP 2022568380 A JP2022568380 A JP 2022568380A JP WO2021229212 A5 JPWO2021229212 A5 JP WO2021229212A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally
- cell
- ipsc
- nucleic acid
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims description 113
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 75
- 150000007523 nucleic acids Chemical group 0.000 claims description 68
- 108091008874 T cell receptors Proteins 0.000 claims description 56
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 56
- 206010028980 Neoplasm Diseases 0.000 claims description 40
- 108020004707 nucleic acids Proteins 0.000 claims description 38
- 102000039446 nucleic acids Human genes 0.000 claims description 38
- 108090000623 proteins and genes Proteins 0.000 claims description 37
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 34
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 34
- 239000000427 antigen Substances 0.000 claims description 34
- 108091007433 antigens Proteins 0.000 claims description 34
- 102000036639 antigens Human genes 0.000 claims description 34
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 30
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 29
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 22
- 201000011510 cancer Diseases 0.000 claims description 21
- 210000004027 cell Anatomy 0.000 claims description 20
- 238000003776 cleavage reaction Methods 0.000 claims description 16
- 230000007017 scission Effects 0.000 claims description 16
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 14
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 230000002255 enzymatic effect Effects 0.000 claims description 9
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims description 8
- 125000000539 amino acid group Chemical group 0.000 claims description 8
- 238000002659 cell therapy Methods 0.000 claims description 8
- 230000010354 integration Effects 0.000 claims description 8
- 210000003705 ribosome Anatomy 0.000 claims description 8
- 102000004961 Furin Human genes 0.000 claims description 7
- 108090001126 Furin Proteins 0.000 claims description 7
- 108020004705 Codon Proteins 0.000 claims description 6
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 4
- 102000000440 Melanoma-associated antigen Human genes 0.000 claims description 4
- 108050008953 Melanoma-associated antigen Proteins 0.000 claims description 4
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 4
- 230000000735 allogeneic effect Effects 0.000 claims description 4
- 238000002619 cancer immunotherapy Methods 0.000 claims description 4
- 210000002443 helper t lymphocyte Anatomy 0.000 claims description 4
- 239000000833 heterodimer Substances 0.000 claims description 4
- 239000000710 homodimer Substances 0.000 claims description 4
- 239000003550 marker Substances 0.000 claims description 4
- 238000012737 microarray-based gene expression Methods 0.000 claims description 4
- 238000012243 multiplex automated genomic engineering Methods 0.000 claims description 4
- 230000006798 recombination Effects 0.000 claims description 4
- 238000005215 recombination Methods 0.000 claims description 4
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims description 3
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims description 3
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 claims description 3
- 210000000349 chromosome Anatomy 0.000 claims description 3
- 210000001519 tissue Anatomy 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 108700028369 Alleles Proteins 0.000 claims description 2
- 102100032912 CD44 antigen Human genes 0.000 claims description 2
- 102100030801 Elongation factor 1-alpha 1 Human genes 0.000 claims description 2
- 108010012015 GVYDGREHTV Proteins 0.000 claims description 2
- 102000050057 Goosecoid Human genes 0.000 claims description 2
- 108700031316 Goosecoid Proteins 0.000 claims description 2
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims description 2
- 101000920078 Homo sapiens Elongation factor 1-alpha 1 Proteins 0.000 claims description 2
- 101000819088 Homo sapiens Transcription factor GATA-6 Proteins 0.000 claims description 2
- -1 Mixl1 Proteins 0.000 claims description 2
- 229930193140 Neomycin Natural products 0.000 claims description 2
- 102000001183 RAG-1 Human genes 0.000 claims description 2
- 108060006897 RAG1 Proteins 0.000 claims description 2
- 102100021382 Transcription factor GATA-6 Human genes 0.000 claims description 2
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 claims description 2
- 101001062354 Xenopus tropicalis Forkhead box protein A2 Proteins 0.000 claims description 2
- 210000002203 alpha-beta t lymphocyte Anatomy 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 230000003115 biocidal effect Effects 0.000 claims description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 2
- 108020001507 fusion proteins Proteins 0.000 claims description 2
- 102000037865 fusion proteins Human genes 0.000 claims description 2
- 210000004475 gamma-delta t lymphocyte Anatomy 0.000 claims description 2
- 210000003566 hemangioblast Anatomy 0.000 claims description 2
- 210000000581 natural killer T-cell Anatomy 0.000 claims description 2
- 229960004927 neomycin Drugs 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 239000002243 precursor Substances 0.000 claims description 2
- 101150013400 rag1 gene Proteins 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 230000035897 transcription Effects 0.000 claims description 2
- 238000013518 transcription Methods 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 description 12
- 150000001413 amino acids Chemical group 0.000 description 9
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 description 6
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 230000004927 fusion Effects 0.000 description 5
- 102000018697 Membrane Proteins Human genes 0.000 description 3
- 108010052285 Membrane Proteins Proteins 0.000 description 3
- 101100508818 Mus musculus Inpp5k gene Proteins 0.000 description 3
- 101100366438 Rattus norvegicus Sphkap gene Proteins 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 108091005703 transmembrane proteins Proteins 0.000 description 3
- 102000035160 transmembrane proteins Human genes 0.000 description 3
- 102000002627 4-1BB Ligand Human genes 0.000 description 2
- 108010082808 4-1BB Ligand Proteins 0.000 description 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 230000000139 costimulatory effect Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 1
- 102000001398 Granzyme Human genes 0.000 description 1
- 108060005986 Granzyme Proteins 0.000 description 1
- 108010075704 HLA-A Antigens Proteins 0.000 description 1
- 102000011786 HLA-A Antigens Human genes 0.000 description 1
- 108010088729 HLA-A*02:01 antigen Proteins 0.000 description 1
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 1
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 1
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000004815 positive regulation of T cell activation Effects 0.000 description 1
- 230000016412 positive regulation of cytokine production Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2006903.5 | 2020-05-11 | ||
| GBGB2006903.5A GB202006903D0 (en) | 2020-05-11 | 2020-05-11 | Modified iPSCs |
| PCT/GB2021/051125 WO2021229212A1 (en) | 2020-05-11 | 2021-05-11 | Modified ipscs |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023524853A JP2023524853A (ja) | 2023-06-13 |
| JPWO2021229212A5 true JPWO2021229212A5 (https=) | 2024-04-19 |
| JP2023524853A5 JP2023524853A5 (https=) | 2024-04-19 |
Family
ID=71135035
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022568380A Pending JP2023524853A (ja) | 2020-05-11 | 2021-05-11 | 改変されたｉＰＳＣ |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240016853A1 (https=) |
| EP (1) | EP4149492A1 (https=) |
| JP (1) | JP2023524853A (https=) |
| CN (1) | CN115515606A (https=) |
| AU (1) | AU2021271220A1 (https=) |
| BR (1) | BR112022022654A2 (https=) |
| CA (1) | CA3178047A1 (https=) |
| GB (1) | GB202006903D0 (https=) |
| IL (1) | IL298074A (https=) |
| MX (1) | MX2022014116A (https=) |
| WO (1) | WO2021229212A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL2022714B1 (en) | 2019-03-11 | 2020-09-18 | Academisch Ziekenhuis Leiden | Optimised RAG1 deficient SCID Gene Therapy |
| GB201911957D0 (en) * | 2019-08-20 | 2019-10-02 | Adaptimmune Ltd | Methods of producing haemogenic progenitor cells from pluripotent stem cells |
| GB202111214D0 (en) * | 2021-08-03 | 2021-09-15 | Adaptimmune Ltd | Modified ipscs |
| GB202205572D0 (en) | 2022-04-14 | 2022-06-01 | Adaptimmune Ltd | Engineered T cells |
| AU2024269870A1 (en) * | 2023-05-05 | 2025-11-20 | Board Of Regents, The University Of Texas System | Multi-receptor natural killer cells |
| CN118421559B (zh) * | 2024-07-04 | 2024-09-27 | 成都赛济元生物医药有限公司 | 定向分化淋巴造血前体细胞的小分子组合、试剂盒及方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201313377D0 (en) * | 2013-07-26 | 2013-09-11 | Adaptimmune Ltd | T cell receptors |
| EP3170896B1 (en) * | 2014-07-18 | 2020-03-11 | Kawamoto, Hiroshi | Production method for pluripotent stem cells having antigen-specific t cell receptor gene |
| KR102654784B1 (ko) * | 2014-07-18 | 2024-04-04 | 사이아스 가부시키가이샤 | 다능성 줄기세포로부터 세포-기반 면역요법용 t 세포를 유도하는 방법 |
| MX2018005274A (es) * | 2015-10-30 | 2019-09-19 | The Regents Of The Universtiy Of California | Metodos para la generacion de celulas-t a partir de celulas madre y metodos inmunoterapeuticos que utilizan las celulas-t. |
| SMT202100564T1 (it) * | 2016-04-08 | 2022-01-10 | Adaptimmune Ltd | Recettori di cellule t |
| US11377637B2 (en) * | 2016-04-15 | 2022-07-05 | Memorial Sloan Kettering Cancer Center | Transgenic T cell and chimeric antigen receptor T cell compositions and related methods |
| US20190290694A1 (en) * | 2016-12-21 | 2019-09-26 | Cellectis | Stably enginereed proteasome inhibitor resistant immune cells for immunotherapy |
| WO2018191490A1 (en) * | 2017-04-13 | 2018-10-18 | The Trustees Of The University Of Pennsylvania | Use of gene editing to generate universal tcr re-directed t cells for adoptive immunotherapy |
| US12350312B2 (en) * | 2017-09-06 | 2025-07-08 | Fred Hutchinson Cancer Center | Methods for improving adoptive cell therapy |
| CN112752838A (zh) * | 2018-07-26 | 2021-05-04 | 国立大学法人京都大学 | 制备引入外源抗原受体的细胞的方法 |
| GB201911953D0 (en) * | 2019-08-20 | 2019-10-02 | Adaptimmune Ltd | T cell production fram RAG inacivated iPSCs |
-
2020
- 2020-05-11 GB GBGB2006903.5A patent/GB202006903D0/en not_active Ceased
-
2021
- 2021-05-11 US US17/924,926 patent/US20240016853A1/en active Pending
- 2021-05-11 IL IL298074A patent/IL298074A/en unknown
- 2021-05-11 AU AU2021271220A patent/AU2021271220A1/en active Pending
- 2021-05-11 JP JP2022568380A patent/JP2023524853A/ja active Pending
- 2021-05-11 BR BR112022022654A patent/BR112022022654A2/pt unknown
- 2021-05-11 CN CN202180034530.6A patent/CN115515606A/zh active Pending
- 2021-05-11 EP EP21727514.8A patent/EP4149492A1/en not_active Withdrawn
- 2021-05-11 CA CA3178047A patent/CA3178047A1/en active Pending
- 2021-05-11 WO PCT/GB2021/051125 patent/WO2021229212A1/en not_active Ceased
- 2021-05-11 MX MX2022014116A patent/MX2022014116A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12404492B2 (en) | Methods for enhancing efficacy of therapeutic immune cells | |
| JP7451858B2 (ja) | クローディン６特異的免疫受容体およびｔ細胞エピトープ | |
| Xue et al. | Induced pluripotent stem cell-derived engineered T cells, natural killer cells, macrophages, and dendritic cells in immunotherapy | |
| US20240024476A1 (en) | CAR Cells and Polyspecific Binding Molecules for Treating Solid Tumor | |
| Ho et al. | Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction | |
| Butler et al. | Human cell‐based artificial antigen‐presenting cells for cancer immunotherapy | |
| JP6161098B2 (ja) | Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞 | |
| JP7252135B2 (ja) | 遺伝子療法 | |
| JP2016539929A (ja) | 免疫療法のためのポリクローナルγδＴ細胞 | |
| KR20220031541A (ko) | 항-bcma car t 세포의 제조 | |
| Zhang et al. | Genetic engineering with T cell receptors | |
| CN117987435A (zh) | 氧依赖性嵌合抗原受体表达及其应用 | |
| JPWO2021229212A5 (https=) | ||
| US20230133564A1 (en) | Cd3-fusion protein and uses thereof | |
| US20240299452A1 (en) | Rapamycin and Cell Therapy | |
| US20250009800A1 (en) | Methods for cancer immunotherapy | |
| HK40086170A (en) | Methods for enhancing efficacy of therapeutic immune cells | |
| KR20220095228A (ko) | 암의 t 세포 치료를 위한 세포독성 효과기 기억 t 세포를 생산하는 방법 | |
| HK40128555A (zh) | 用於产生细胞毒性效应子记忆t细胞以用於癌症的t细胞治疗的方法 | |
| Yee et al. | Recent advances in the use of antigen-specific T cells for the treatment of cancer | |
| Yee | Adoptive cellular therapy for the treatment of cancer | |
| Ahonen et al. | 189. CD40-Ligand Armed Vaccinia Virus for Induction of Anti-Tumor Immune Response | |
| HK1248273B (en) | Methods for enhancing efficacy of therapeutic immune cells | |
| HK1248273A1 (en) | Methods for enhancing efficacy of therapeutic immune cells |